Abstract
Inspired by previously discovered enhanced analgesic efficacy between soluble epoxide hydrolase (sEH) and phosphodiesterase 4 (PDE4) inhibitors, we designed, synthesized and characterized 21 novel sEH/PDE4 dual inhibitors. The best of these displayed good efficacy in in vitro assays. Further pharmacokinetic studies of a subset of four selected compounds led to the identification of a bioavailable dual inhibitor N-(4-methoxy-2-(trifluoromethyl)benzyl)-1-propionylpiperidine-4-carboxamide (MPPA). In a lipopolysaccharide induced inflammatory pain rat model, MPPA rapidly increased in the blood (Tmax = 30 min; Cmax = 460 nM) after oral administration of 3 mg/kg and reduced inflammatory pain with rapid onset of action correlating with blood levels over a time course of 4 h. Additionally, MPPA does not alter self-motivated exploration of rats with inflammatory pain or the withdrawal latency in control rats.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3541-3550 |
| Number of pages | 10 |
| Journal | Journal of Medicinal Chemistry |
| Volume | 61 |
| Issue number | 8 |
| DOIs | |
| State | Published - Apr 26 2018 |
Fingerprint
ASJC Scopus subject areas
- Molecular Medicine
- Drug Discovery
Cite this
Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain. / Blöcher, René; Wagner, Karen M.; Gopireddy, Raghavender R.; Harris, Todd R.; Wu, Hao; Barnych, Bogdan; Hwang, Sung Hee; Xiang, Yang Kevin; Proschak, Ewgenij; Morisseau, Christophe; Hammock, Bruce D.
In: Journal of Medicinal Chemistry, Vol. 61, No. 8, 26.04.2018, p. 3541-3550.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain
AU - Blöcher, René
AU - Wagner, Karen M.
AU - Gopireddy, Raghavender R.
AU - Harris, Todd R.
AU - Wu, Hao
AU - Barnych, Bogdan
AU - Hwang, Sung Hee
AU - Xiang, Yang Kevin
AU - Proschak, Ewgenij
AU - Morisseau, Christophe
AU - Hammock, Bruce D.
PY - 2018/4/26
Y1 - 2018/4/26
N2 - Inspired by previously discovered enhanced analgesic efficacy between soluble epoxide hydrolase (sEH) and phosphodiesterase 4 (PDE4) inhibitors, we designed, synthesized and characterized 21 novel sEH/PDE4 dual inhibitors. The best of these displayed good efficacy in in vitro assays. Further pharmacokinetic studies of a subset of four selected compounds led to the identification of a bioavailable dual inhibitor N-(4-methoxy-2-(trifluoromethyl)benzyl)-1-propionylpiperidine-4-carboxamide (MPPA). In a lipopolysaccharide induced inflammatory pain rat model, MPPA rapidly increased in the blood (Tmax = 30 min; Cmax = 460 nM) after oral administration of 3 mg/kg and reduced inflammatory pain with rapid onset of action correlating with blood levels over a time course of 4 h. Additionally, MPPA does not alter self-motivated exploration of rats with inflammatory pain or the withdrawal latency in control rats.
AB - Inspired by previously discovered enhanced analgesic efficacy between soluble epoxide hydrolase (sEH) and phosphodiesterase 4 (PDE4) inhibitors, we designed, synthesized and characterized 21 novel sEH/PDE4 dual inhibitors. The best of these displayed good efficacy in in vitro assays. Further pharmacokinetic studies of a subset of four selected compounds led to the identification of a bioavailable dual inhibitor N-(4-methoxy-2-(trifluoromethyl)benzyl)-1-propionylpiperidine-4-carboxamide (MPPA). In a lipopolysaccharide induced inflammatory pain rat model, MPPA rapidly increased in the blood (Tmax = 30 min; Cmax = 460 nM) after oral administration of 3 mg/kg and reduced inflammatory pain with rapid onset of action correlating with blood levels over a time course of 4 h. Additionally, MPPA does not alter self-motivated exploration of rats with inflammatory pain or the withdrawal latency in control rats.
UR - http://www.scopus.com/inward/record.url?scp=85046004451&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046004451&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.7b01804
DO - 10.1021/acs.jmedchem.7b01804
M3 - Article
C2 - 29614224
AN - SCOPUS:85046004451
VL - 61
SP - 3541
EP - 3550
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
SN - 0022-2623
IS - 8
ER -